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Novel members of quinoline 
compound family enhance insulin 
secretion in RIN-5AH beta cells and 
in rat pancreatic islet microtissue
Z. Orfi1, F. Waczek2, F. Baska2, I. Szabadkai2, R. Torka1, J. Hartmann3, L. Orfi2,4 & A. Ullrich1
According to clinical data, some tyrosine kinase inhibitors (TKIs) possess antidiabetic effects. Several 
proposed mechanisms were assigned to them, however their mode of action is not clear. Our hypothesis 
was that they directly stimulate insulin release in beta cells. In our screening approach we demonstrated 
that some commercially available TKIs and many novel synthesized analogues were able to induce 
insulin secretion in RIN-5AH beta cells. Our aim was to find efficient, more selective and less toxic 
compounds. Out of several hits, we chose members from a compound family with quinoline core 
structure for further investigation. Here we present the studies done with these novel compounds and 
reveal structure activity relationships and mechanism of action. One of the most potent compounds 
(compound 9) lost its affinity to kinases, but efficiently increased calcium influx. In the presence of 
calcium channel inhibitors, the insulinotropic effect was attenuated or completely abrogated. While 
the quinoline TKI, bosutinib substantially inhibited tyrosine phosphorylation, compound 9 had no such 
effect. Molecular docking studies further supported our data. We confirmed that some TKIs possess 
antidiabetic effects, moreover, we present a novel compound family developed from the TKI, bosutinib 
and optimized for the modulation of insulin secretion.
Tyrosine kinase inhibitors (TKIs) have proven anti-diabetic effect in different animal models and in clinical can-
cer patients as well1–4. How these TKIs could relieve diabetic symptoms is not completely understood yet. Their 
potential mechanism of actions leading to hypoglycemic effects have been recently summarized in several review 
papers5–8. According to the current knowledge the inhibition of c-Abl, PDGFR and VEGFR are considered as 
important factors in the remission of diabetes, nevertheless it does not give a full explanation for their mode of 
action. There are only a few studies available that investigated the direct effects of TKIs in beta cells. Reportedly, 
imatinib induced insulin secretion in the mouse pancreatic beta cell line NIT-19. However in another study per-
formed on human and rat pancreatic islets imatinib did not affect insulin secretion10. The latter observation is 
supported by other findings obtained with MIN6 mouse beta cells, mouse and human islets11. In contrast to 
imatinib, sunitinib was able to increase insulin level and decrease blood glucose level in a non-obese, sponta-
neously diabetic Torii rats animal model3. Based on these observations we hypothesized that insulin secretion 
could be directly stimulated by TKIs in beta cells. First we studied the effects of commercially available TKIs by 
using an insulin ELISA assay and found that some of them were able to induce insulin release in RIN-5AH beta 
cells. Because this cell line was responsive to various insulin secretagogue drugs (GLP-1, exenatide, glibenclamide 
and PDE4 inhibitors), it was chosen as a model for the studies of unknown compounds. Out of the 6 commer-
cially available TKIs (sunitinib, imatinib, bosutinib, tivantinib, sorafenib and dasatinib) that we tested for insulin 
secretion, sunitinib was the most effective (Supplementary Figs 1 and 2). With the purpose of finding additional, 
more efficient and preferably less toxic candidates, we established a rationally designed compound library. The 
library consisted of 558 various molecules including the 6 commercial TKIs. Their kinase targets were known 
or predicted to overlap with the target profile of sunitinib. Most of the hit compounds could be classified into 
different groups according to their core structures. We identified strong hits with the following core structures: 
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N-phenylpyrimidin-2-amine; 1,6-naphthyridine; quinoline; 5,6,7,8-tetrahydrobenzothiopheno[2,3-d]pyrimi-
dine; quinazoline; 2-[(E)-styryl]quinazoline; indoline and quinoxaline. In this article we would like to report our 
results achieved with the quinoline derivatives only. After choosing this compound family for further investiga-
tion, additional derivatives were synthesized beyond the compounds included in the initial library. We demon-
strate altogether 79 novel quinoline molecules in this paper that can be considered as derivatives of bosutinib, 
however they displayed notable differences in respect to insulin secretion and protein tyrosine phosphorylation. 
Interestingly, we found that minor modifications of the molecular structure unfolded an altered mechanism of 
action, which could be either based on the induction of calcium influx or tyrosine kinase inhibition. In this paper 
we demonstrate a structure activity relationship (SAR) analysis also that is necessary to interpret the transition 
from the TKI property towards the calcium influx inducer effect. Further on we focus on the characterization of 
the highly potent quinoline compound, 9 which induces insulin secretion in RIN-5AH cells and 3D rat pancreatic 
islet microtissues.
Results
Structure activity relationships (SAR) of quinoline derivatives. In the primary screen there were 552 
novel synthesized compounds and 6 commercially available TKIs included. We found that sunitinib produced a 
superior effect over the other 5 commercial compounds and showed a significantly improved insulin secretion 
over bosutinib as well (Supplementary Fig. 2). By further searching for additional active candidates in our screen-
ing setup, we achieved a 10% hit rate (data not shown). Out of these hits, the highly potent quinoline compound 
family was selected for further investigation. There were altogether 80 quinoline molecules tested for insulin 
secretion, including bosutinib that is sharing the same quinoline core (Supplementary Table 1). The prominent 
structural differences between bosutinib and these novel quinoline derivatives are the disposition of CN group 
from R3 to R2 (3-CN to 2-CN), moreover the replacement of R6 and R7 groups to smaller substituents e.g. OCH3 
or F (compounds 8, 9, 10, 11). These compounds produced 6–10 times stronger insulinotropic effect compared to 
bosutinib. The Br, F or CF3 functional groups in R8 position also contributed to the effect (compounds 7, 13, 14), 
however, an addition of a F to R6 completely abolished the effect (compound 33). The displacement of CN group 
from R2 to R3 significantly attenuated the effect (compound 15). When OCH3 or F was present in R6 or R7 
positions, the replacement of R2 CN groups to CONH2, methanesulfonamidomethyl, COOH, CH2NH2 or CH3 
(compounds 17, 21, 22, 32, 34) dramatically reduced the effect. The above described SARs of compounds, with 
the 2,4-dichloro-5-methoxy-anilino group at R4 position, are displayed in Table 1. Further important SARs could 
be specified when substituents were exchanged in R4 position. These substituents were classified into 3 groups 
according to their impact on the stimulation of insulin secretion measured by ELISA (Fig. 1).
For further tests, one of the most potent quinoline derivative was chosen (compound 9). It stimulated insulin 
secretion in RIN-5AH beta cells in a concentration and time dependent manner. The EC50 was determined at 
2.38 μ M, whereas the maximal effect was observable between 10–20 μ M. Glibenclamide (GBA) was used as a pos-
itive control, its EC50 was 61.86 μ M and the maximal insulin response was detected at 100–200 μ M. It is impor-
tant to notice that the maximal effect of insulin secretion was much higher in case of compound 9 treatment. 
ID R2 R3 R4 R6 R7 R8 Insulin (%) Calcium (AUC) pTyr (%) Viability (%)
Compound 7 CN (2,4-dichloro-5-methoxy-anilino) Br 116.1 ± 13.2
Compound 8 CN (2,4-dichloro-5-methoxy-anilino) OCH3 F ****115,8 ± 12 ****89.5 ± 14 66.0 ± 13.5 94.7 ± 6.7
Compound 9 CN (2,4-dichloro-5-methoxy-anilino) F ****120.8 ± 6.6 ****92.5 ± 12.8 114.6 ± 22.26 84.7 ± 4.3
Compound 10 CN (2,4-dichloro-5-methoxy-anilino) F 89.4 ± 12.6
Compound 11 CN (2,4-dichloro-5-methoxy-anilino) OCH3 78.2 ± 11.7
Compound 12 CN (2,4-dichloro-5-methoxy-anilino) OCH3 ## ***74,0 ± 6 5.3 ± 2,5 *24.0 ± 3.8 *60.8 ± 16.7
Compound 13 CN (2,4-dichloro-5-methoxy-anilino) F 69.9 ± 10.5
Compound 14 CN (2,4-dichloro-5-methoxy-anilino) CF3 57.9 ± 14.1
Compound 15 CN (2,4-dichloro-5-methoxy-anilino) OCH3 F 36,3 ± 3 9.5 ± 4.2 **35.6 ± 6.7 93.5 ± 5.1
Compound 17 CONH2 (2,4-dichloro-5-methoxy-anilino) OCH3 33.6 ± 8.2
Compound 21 # (2,4-dichloro-5-methoxy-anilino) F 20.4 ± 5.7
Compound 22 COOH (2,4-dichloro-5-methoxy-anilino) OCH3 20.3 ± 4.8
Compound 32 CH2NH2 (2,4-dichloro-5-methoxy-anilino) F −2,0 ± 10 3.4 ± 0.2 103.1 ± 3.3
Compound 33 CN (2,4-dichloro-5-methoxy-anilino) F Br −5.3 ± 5.5
Compound 34 CH3 (2,4-dichloro-5-methoxy-anilino) OCH3 −7.9 ± 2.3
Bosutinib CN (2,4-dichloro-5-methoxy-anilino) OCH3 ### 14,0 ± 2.8 7.1 ± 1.4 ***18.6 ± 1.0 94.0 ± 5.8
Table 1.  Structure activity relationships (SAR) of quinoline compounds with (2,4-dichloro-5-methoxy-
anilino) group at R4 position.  Insulin is represented in % compared to DMSO treated cells (DMSO = 0%), 
Calcium influx is represented in AUC calculated from 50s–325 s (taking the period from 0–35 s as baseline), 
phopsho-tyrosine levels (pTyr) are indicated in % compared to DMSO treated cells (DMSO = 0%), viability 
values represent the % of healthy cells after treatments, compared to DMSO (where DMSO = 100%). 
All measurements indicated in the table were performed in RIN-5AH beta cells (n ≥ 3; SEM; t-test or 
ANOVA).#Methanesulfonamidomethyl. ##3-aminopropoxy. ###3-(4-methylpiperazin-1-yl) propoxy.
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The EC50 of sunitinib was 2.89 μ M (Fig. 2a–c). Kinetic measurements revealed quick acting characteristics for 
compound 9 and after 10 min treatment a significant insulin release was detected already. Other compounds like 
GBA, sunitinib, bosutinib and a non-secretagogue quinoline compound, 32 showed different kinetics and their 
on-set effects were observable at 60–120 min (Fig. 2d). The insulinotropic action of compound 9 was confirmed 
in rat islet microtissues. Compared to RIN-5AH cells, the islets seemed to be less sensitive not only to compound 
9 but also to GLP-1 and GBA (Fig. 2e).
Compound 9 is not targeting kinases. Results of the kinetic experiments already suggested a differ-
ent mechanism of action for compound 9 compared to bosutinib and sunitinib. Bosutinib and sunitinib are 
reported to hit many kinases besides their main targets src, Abl and VEGFR, PDGFR, KIT, RET12,13. With the 
purpose to ascertain what targets could be different or common between sunitinib, bosutinib and compound 9, 
the substances were tested against 392 non-mutant and 59 mutant kinases (386 non-mutants and 56 mutants 
in case of bosutinib) in a competitive binding assay under identical conditions. The selectivity panel was pro-
vided by DiscoverX (Fremont). Surprisingly we found that however the predicted target profile of compound 
9 should overlap with the target profile of bosutinib or sunitinib, as the results are showing there were no high 
affinity binders identified for compound 9. Besides that, sunitinib and bosutinib hit 219 and 147 non-mutant 
Figure 1. The quinoline core structure and examples of R4 substituents that differently influenced 
insulin secretion in RIN-5AH beta cells. Quinoline core structure is displayed at top. The three groups of R4 
substituents are displayed below. “Preferable” represent a group of molecules where at least 4 derivatives with 
the same R4 substituent increased insulin secretion by at least 40% (first row) or if exclusive replacement of 
R4 group didn’t decrease insulin secretion of an efficient derivative (second row). “Tolerable” R4 groups don’t 
necessarily spoil the effect, depending on the R6,7,8 substituents. Third group represents derivatives with 
undesirable changes where if replacements carried out solely with any of the indicated R4 substituents spoiled 
the effect of its efficient derivative. Q denotes connection to quinoline ring through R4 position. For more 
details please see Supplementary Table 1.
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kinases respectively (Supplementary Fig. 3). Next, we selected bosutinib and some of the intermediate derivatives 
to confirm non-tyrosine kinase inhibitory activity and to find out the SAR how total tyrosine phosphorylation 
(pTyr) is affected by the different substituents on the quinoline ring. The pTyr level was significantly reduced after 
treatments with bosutinib, compound 12 and compound 15, on the other hand for compound 8 and compound 
9 this was not the case. Compound 9 differs from compound 8 only by lacking the 6-methoxy group (6-OCH3) 
on the quinoline ring. A nonsignificant but moderately reduced tyrosine phosphorylation caused by compound 8 
suggested that the 6-OCH3 might also play a role in targeting kinases, because the removal of this group seemed 
to further impair the TKI effect (Fig. 3). Results of antibody controls are indicated in Supplementary Fig. 4. The 
Figure 2. Concentration and time dependent insulin responses of beta cells upon the treatment with 
quinolines, GBA and bosutinib. Values are indicated in %, compared to DMSO treated cells (DMSO = 0%). 
(a–c) Graphs representing the insulinotropic effects of glibenclamide, compound 9 and sunitinib in RIN-5AH 
cells treated for 2 h. The EC50 value for compound 9 was detected at 2.38uM for GBA at 61.86 uM and for 
sunitinib at 2.89 uM. The maximal effect was much higher in the case of compound 9 (n = 4-8; SEM). (d) TKI 
compounds sunitinib and bosutinib had a different kinetics and their effects developed later. Compound 9 
was able to significantly increase insulin secretion after 30 min compared to DMSO and to all other compound 
treatments at indicated time points (30 min, 60 min and 120 min; ****p < 0.0001). After 120 min treatment 
with glibenclamide (GBA) and sunitinib (SU) insulin secretion was significantly elevated (****p < 0.0001), 
bosutinib (BOS) treatment showed a lower level of significance (p = 0.0217), while a non-active quinoline 
analogue, compound 32, caused no significant insulin secretion (n = 4; SEM; ANOVA/Tukey). (e) Validation 
of insulinotropic effect of compound 9 (Cpd 9) and control compounds in rat islet microtissue and comparison 
to RIN-5AH beta cells. Cells and islets were treated for 2 h with 5 uM compound 9, 0.3 uM GLP-1 and 100 uM 
glibenclamide (GBA). Rat islet microtissues proved to be less sensitive, but compound 9 and GLP-1 showed 
significant increase in insulin secretion compared to DMSO (n = 4-8, SEM, t-test, *p < 0.05; **p < 0.01; 
****p < 0.001).
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markedly reduced TKI effect caused by compound 9 was confirmed by western blotting. Furthermore, no changes 
were visible in phospho-serine nor in phospho-threonine levels by western blotting (Supplementary Fig. 5).
Docking simulations with Abl and Src kinases in Schrodinger Suite suggest a non-TKI property 
for compound 9. Compound 9 lost its affinity to Abl and Src kinases, which are main targets of the quino-
line TKI, bosutinib. Although compound 9 and bosutinib share the same core structure, they have a differently 
positioned nitrile group (CN) on the quinoline ring as mentioned above. It was reported that this R3 CN group in 
bosutinib played an important role in the binding to Abl kinase14. By examining the binding mode of bosutinib, 
hydrogen bonds could be observed with the hinge region of both kinases (Fig. 4). In the case of compound 9, 
Glide did not found any hydrogen bonds with the ATP binding sites and the docking scores (Abl: − 6.896 kcal/
mol, Src: − 6.362 kcal/mol) were only moderate as well. These results are in good correlation with the biochemical 
data, as compound 9 does not inhibit Abl nor Src kinases.
Quinoline derivatives induce Ca2+ influx in RIN-5AH beta cells. Elevated intracellular calcium con-
centration ([Ca2+]i) is one of the most important secondary messenger mechanism that triggers the exocytosis 
of insulin vesicles in beta cells15. It was shown that kinases most likely did not play a role in the mode of action of 
the tested 2-CN substituted quinoline derivative compound 9. By this we hypothesized that another mechanism 
was responsible and investigated if calcium influx was affected. Compound 9 and GBA treated RIN-5AH cells 
were tested for insulin secretion in HBSS buffer with or without Ca2+/Mg2+ (HBSS+ + or HBSS− ). Neither GBA 
nor compound 9 could stimulate insulin release if HBSS− buffer was employed. These results denoted a calcium 
dependent mechanism. In our experiments, compounds with tyrosine kinase inhibitory property and character-
ized by a CN group in R3 position were not able to increase calcium influx (compounds 12, 15 and bosutinib), 
conversely the other two 2-CN derivatives (compound 8 and 9) showed positive results. The impacts of com-
pound treatments on Ca2+ influx are illustrated in Fig. 5. All treatments were done at 5 μ M, except for GBA where 
200 μ M was applied. Additional reference compounds were also used in the assay. Quinidine, chloroquine, meflo-
quine (quinoline compounds) and the fluoroquinolone drugs gatifloxacin and levofloxacin were described to 
have an inhibitory effect on KATP channels which may lead to membrane depolarization and subsequent increase 
of [Ca2+]i in beta cells16–19. In RIN-5AH beta cells the insulin secretion was stimulated by quinidine and chloro-
quine at 50 μ M but not by fluoroquinolones. The calcium influx caused by quinidine was only detectable at much 
higher concentrations (Supplementary Figs 6 and 7). These results clarified that the primary mechanism of com-
pound 9 was linked to the opening of calcium channels located in the plasma membrane and was not dependent 
on the mobilization of Ca2+ from the internal calcium stores. Evidently compound 9 was more effective compared 
to GBA, quinidine or chloroquine in respect to insulin secretion and calcium influx.
Compound 9 induces membrane depolarization in RIN-5AH beta cells. Membrane depolarization 
or other stimuli can induce and regulate the opening of voltage dependent calcium channels (VDCC) which can 
subsequently lead to increased [Ca2+]i in the cells20,21. We used whole cell patch-clamp recordings to check if the 
calcium influx induced by compound 9 was a result of membrane depolarization. In our experiment a shift in 
membrane potential from − 70 mV up to − 20 mV (50 μ M) or 0 mV (500 μ M) was registered in current clamp 
(CC) mode. In cells treated with GBA (30 s; 500 μ M) the depolarization was transient (approx. 90 s). The analo-
gous application of compound 9, in contrast, caused a sustained depolarization lasting at least for the duration of 
Figure 3. Total pTyr level in RIN-5AH beta cells, after treatment with various quinoline derivatives. 
(a) Gated cells for evaluation. (b) Representative graphs of fluorescence intensities measured in FL2-H. 
Fluorescence which is proportional to pTyr level is significantly reduced after treatment with compound 15, 
compound 12 and bosutinib, while compound 8 and compound 9 didn’t affect tyrosine phosphorylation. (c) 
Quantitative evaluation of total pTyr levels in RIN-5AH cells after treatment with quinoline compounds and 
bosutinib (BOS) at 5 μ M for 2 h. Grey bars indicate treatments with 2-ciano-quinoline derivatives, black bars 
stand for 3-ciano-quinolne derivatives. Data is normalized to samples incubated with isotype control Ab and 
represented in % to DMSO (DMSO set to 100%). (n = 3; SEM; ANOVA/Tukey).
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the recording (240 s; n = 3). The same difference in the kinetic properties of the responses to GBA and compound 
9, respectively, were observed in voltage-clamp recordings. The current intensity returned to basal value after 
30 s in case of GBA, while in case of compound 9 it took approximately 3 min (Fig. 6). Furthermore, stimulation 
with compound 9 caused an immediate increase in inward current, unlike GBA where a short delayed response 
was registered, which could also refer to some differences in their mechanism of action. Interestingly, lower and 
higher concentrations of compound 9 (50–500 μ M) showed comparable effect on inward current in VC mode 
(− 400–500 pA), which in comparison to GBA (− 40 pA) was apparently higher. A change in membrane capaci-
tance was also detectable during compound stimulation, which indicated that exocytotic events happened in the 
cells22 (data not shown).
Insulinotropic effect of compound 9 is dependent on Ca2+ and K+ currents in RIN-5AH beta 
cells. To further investigate the mechanism of action of compound 9, combinatorial treatments were per-
formed by using small molecular inhibitors that interfere or block Ca2+ or K+ currents. Additionally, combination 
with inhibitors of MEK-ERK pathway and the CAMKII protein were also tested, since compound 9 upregulated 
ERK and CAMKII protein phosphorylation in RIN-5AH cells as well (see western blot results). Ion channel mod-
ulators that negatively affect insulin release were used in combination with compound 9. High concentrations of 
single treatments with diazoxide (DAO), verapamil (VER) and efonidipine (EFD) were able to decrease insulin 
secretion in RIN-5AH beta cells significantly (Fig. 7a). By applying excessive amount of the KATP opener drug 
DAO (50 μ M and 100 μ M), it was able to reduce the concentration of secreted insulin in compound 9 treated cells. 
(Fig. 7b). Combinatorial treatments with L-type Ca2+ channel blockers, verapamil (VER) and nifedipine (NFD) 
resulted in a decreased or abrogated insulin secretion. (Fig. 7c). Applying 1 μ M of the L-and T-type channel 
blocker efonidipine (EFD) significantly reduced and at 10 μ M it completely abolished the effect of compound 9 
(Fig. 7d). We used two types of MEK inhibitors (PD184352 and U0126) in combination with compound 9 to see 
how insulin secretion is altered if compound 9 induced ERK activation is blocked. Interestingly they produced 
different results. It was described by others that U0126 had the ability to block calcium influx and therefore hinder 
amino acid induced insulin secretion23. We were curious to see if it is also able to block the effect of compound 
9. We found that PD184352 abrogated the insulinotropic effect of compound 9 while U0126 had no such effect 
(Fig. 7e). The insulinotropic action of compound 9 was abolished by KN-62, an allosteric CAMKII inhibitor, 
which might additionally inhibit potassium channels too24 (Fig. 7f). The effects of GLP-1 and sunitinib were also 
investigated by combination treatments. The results suggested a distinct mechanism of action for compound 9, 
as neither VER nor NFD were able to reduce the effect of GLP-1 and sunitinib significantly, indicating that they 
primarily stimulated insulin secretion without the involvement of L-type Ca2+ channels (Supplementary Fig. 8).
Compound 9 activates CAMKII and ERK1/2 in RIN-5AH beta cells. Exocytosis and calcium influx 
related signaling pathways were checked by western blot studies. The calmodulin-dependent kinase II (CAMKII) 
is known to play a major role in mediating the effects of Ca2+ in the cells and was described to take part in 
Figure 4. Docking poses of compound 9 (orange) compared to bosutinib (green) on the ATP binding site 
of Abl and Src. H-bonds are marked with yellow lines. Bosutinib forms hydrogen bond with the hinge region of 
both kinases (Abl – Met318; Src – Met341).
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the regulation of insulin secretion as well. Its activation correlated with insulin secretion and proved to have 
an important role in the regulation of glucose dependent insulin secretion in beta cells25–27. It is also known 
that treatments with various insulin secretagogue drugs (e.g. glibenclamide) involve ERK1/2 phosphorylation 
that may also correlate with an increased insulin secretion28–31. The activation of ERK1/2 protein can be further 
Figure 5. The mechanism of action of Compund 9 is linked to extracellular calcium influx. (a) RIN-5AH 
cells secreted significantly lower amount of insulin in HBSS− compared to HBSS+ + buffer when treated 
with compound 9. Glibenclamide (GBA) had no effect in HBSS− either (5μ M for VCC981125 and 100μ M for 
GBA; n = 4–8; SEM; t-test; *p < 0.05; **p < 0.01; ****p < 0.001). (b) Calcium influx was monitored on FACS. 
Graph displays the changes of [Ca]i in Fluo-4AM loaded RIN-5AH beta cells. Arrow indicates the addition of 
compounds (at 35 sec). Each data point represents the mean of a 5s gate. Outer dashed line represents borders 
of standard error (200 μ M for GBA and 5 μ M for other compounds; n = 3–5) (c) Quantitative evaluation of 
calcium influx representing the AUC (area under the curve) values. The baseline was defined from 0-35sec and 
the area was calculated from 50-325 sec. Grey bars indicate the 2-ciano-quinoline derivatives, black bars the 
3-ciano-quinolne derivatives and white bars the negative (DMSO) and positive (GBA) controls (n = 3–5; SEM; 
t-test). (d) Representative graphs illustrating calcium influx measured on FACS. A gap denotes the addition of 
compounds to the cells. Compound 9 and GBA increased calcium influx in Ca2+ /Mg2+ containing, but not in 
Ca2+ /Mg2+ free buffer. The signal proportional to free Ca2+ level could be quenched by using EGTA in both 
cases. Thapsigargin (TG) was used as positive control to validate the experiment. It induced calcium release 
from internal Ca2+ stores in HBSS− . (e) Images showing the Fluo-4 loaded RIN-5AH beta cells treated by 
various compounds. First column represents cells before treatment, second column after treatment.
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beneficial to beta cells by promoting cell survival, which was described in a recent study with imatinib32. Time 
dependent treatments were performed with compound 9 in RIN-5AH cells and results were analyzed by western 
blot. Short term treatments showed evidence for activation of calcium influx through upregulation of CAMKII 
and ERK1/2. It was also noticeable that protein phosphorylation and upregulation preceded insulin secretion, 
therefore the activation of CAMKII and ERK1/2 proteins could be a part of an early mechanism of the insulin 
response triggered by compound 9 (Fig. 8a–c). Combination treatments with compound 9 and CAMKII, MEK 
and calcium channel inhibitors were analyzed by western blot too. Pre-treatment with the CAMKII inhibitor 
KN-62 prevented the compound 9 induced activation of both ERK1/2 and CAMKII. The phosphorylation of 
ERK1/2 but not CAMKII was completely blocked in the presence of the MEK inhibitor U0126. Besides that, a 
strong MEK1/2 hyperactivation was observable. This phenomenon is known and was described in other in vitro 
studies using MEK inhibitors or siRNAs targeting the MEK-ERK pathway33,34. Applying 1 μ M of the L- and T-type 
calcium channel blocker efonidipine prevented ERK1/2 but not CAMKII phosphorylation in our experiments. 
The compound induced upregulation of ERK1/2 could be also a result of GPCR activation therefore GLP-1 was 
included as a control compound35–37. For further controls glibenclamide (GBA) and bosutinib (BOS) were used. 
As expected, GBA induced the phosphorylation of CAMKII and activated ERK1/2 via the increased calcium 
influx. GLP-1 upregulated ERK1/2 but not CAMKII. Bosutinib did not affect CAMKII or ERK1/2 phospho-
rylation (Fig. 8d–f). These experiments showed that ERK1/2 and CAMKII are important signaling molecules 
Figure 6. Representative graphs of patch clamp experiments performed in RIN-5AH cells after stimulation 
with glibenclamide (GBA) or Compound 9 (Cpd 9). Vertical dotted lines at 10 s indicate the starting 
timepoint of stimulation, which lasted for 30 s in each case (marked with horizontal lines). (a–c) Current clamp 
measurements after stimulation. (d–f) Voltage clamp measurements after stimulation. Compound 9 (Cpd 9); 
glibenclamide (GBA). Measurements were repeated at least three times on independent cells and gave similar 
results.
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transmitting the insulinotropic effect caused by compound 9. Furthermore they highlight additional differences 
in the mode of action compared to glibenclamide, GLP-1 and also to bosutinib.
Most novel quinoline compounds and compound 9 do not affect cell viability. The compounds 
used in insulin ELISA assays were tested with regard to their long-term effect on cell viability in RIN-5AH cells 
since the doubling time of these cells is more than 24 h. The main purpose of these experiments were to exclude 
the possibility of toxicity, e.g. stress induced insulin secretion38. The quinoline compounds, commercial TKIs 
and other inhibitors that were used in our experiments were tested by CellTiter-Glo. We selected staurosporine 
as a positive control in the assay, which induced strong cell death at 5 μ M after 72 h. Other TKIs reduced the 
Figure 7. Combinatorial treatments with Cpd9 and ion channel modulators and their effects on insulin 
secretion in RIN-5AH cells. (a) Single compound treatments with ion channel modulators and MEK 
inhibitors. DMSO treatment was taken as a reference for calculating the significance. (b) Combination of 
compound 9 (5 μ M) with KATP opener drug, diazoxide (DAO, 10;50,100 μ M), (c) with L-type Ca2+ channel 
inhibitor, verapamil (VER, 1;10;100 μ M) and nifedipine (NFD, 10μ M), (d) with L-/T-type channel inhibitor 
efonidipine (EFD, 1 μ M;10 μ M), (e) with MEK inhibitors, U0126 (U0, 10μ M) and PD184352 (PD, 10 μ M) and 
(f) with CAMKII inhibitor KN-62 (10 μ M). For (b–f) the significance is displayed taking Cpd9 treatment as the 
reference. (n = 4; SEM; 1-way ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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Figure 8. Investigation of the involvement of CAMKII, MEK1/2 and ERK1/2 in compound 9 stimulated 
insulin release. (a–c) Western Blot results of time dependent treatment. Cells were treated with 5 μ M compound 
9 for the indicated time. ERK1/2 and CAMKII were rapidly phosphorylated after treatment. MEK1/2 protein 
was slightly upregulated, however the change was not significant. Graphs are representing the quantitative 
results of western blot experiments. (d–f) Western Blot results of combination treatments in RIN-5AH cells. 
5 μ M compound 9 (Cpd 9) increased CAMKII and ERK1/2 phosphorylation. 10 μ M KN-62 could block the 
stimulatory effect of cpd 9 on CAMKII. It reduced ERK1/2 phosphorylation as well, but didn’t affect pMEK1/2 
level. 10 μ M U0126 didn’t change phosphorylation state of CAMKII but caused a hyperactivation of MEK1/2, 
while completely blocked ERK1/2. 1 μ M efonidipine was enough to reduce pERK1/2 level, but interestingly 
CAMKII could be still stimulated by cpd 9. 200 μ M GBA upregulated CAMKII and ERK1/2. 0.3 μ M GLP-1 
involved ERK1/2 but not CAMKII phosphorylation. 5 μ M bosutinib didn’t affect pCAMKII and pERK1/2 levels. 
Data are normalized to total ERK1/2 (for pERK1/2) or a-tubulin (for pMEK1/2 and pCAMKII). Experiments 
were performed three times and gave similar results. Data was normalized to total protein amount. Significance 
is shown compared to DMSO treatment (n = 3–4; SEM; Two way ANOVA/Dunnett).
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cell viability by 4–24%. From the tested set of quinolines only 12 compounds reduced the cell viability by more 
than 25%. Calcium channel inhibitors and the MEK inhibitor U0126 did not affect cell health. Another MEK 
inhibitor PD184352 disturbed cell viability, therefore U0126 was used in other experiments in combination with 
compound 9. We noticed that high concentration of GBA (200 μ M) also showed a high rate of toxicity in the 
cells. Results of the 72 h cell viability assay can be found in Supplementary Table 2. Dose response measurements 
were performed with compound 9 and we found that cell viability was affected only above 10 μ M after 72 h incu-
bation. We also investigated the effect of compound 9 on the proliferation in RIN-5AH cells by utilizing BrdU 
and propidium iodide (PI) + annexin V (AN) double staining assays. These time dependent treatments further 
support our findings that the compound 9 stimulated insulin secretion was not a consequence of a toxic effect 
(Supplementary Fig. 9a–d).
Discussion
Our initial studies had been focused on the investigation of TKIs, however later on the results lead to the discov-
ery of a novel compound family acting via a different mechanism. We demonstrated that structural modification 
of the TKI bosutinib made it possible to optimize and develop new compounds for the stimulation of insulin 
secretion.
By our screening approach, we identified potent TKIs and a novel quinoline compound family that signif-
icantly increased insulin secretion in RIN-5AH beta cells. We observed that the TKIs mainly targeting c-Abl 
(imatinib and bosutinib) were associated with a less prominent insulinotropic effect and sunitinib was the most 
potent amongst them. Although bosutinib and sunitinib share common kinase targets, in order to identify the 
relevant (and most likely a combination of) ones that play role in the enhancement of insulin secretion, would 
need more investigation. From the quinoline family, compound 9 proved to be more potent than sunitinib, hence 
it was chosen for further characterization. In the kinase affinity assay, 219 hits were identified for sunitinib, 147 for 
bosutinib and no hits were found for compound 9 by using the same cutoffs and concentrations. This result was 
confirmed in further experiments and a distinct mechanism of action involving calcium influx could be assigned 
to compound 9. It is important to notice that increased [Ca]i was only detectable in the presence of extracellular 
calcium, thus calcium release from intracellular calcium stores were primarily not part of the mechanism, more 
importantly extracellular calcium was necessary to exert its insulinotropic effect on RIN-5AH beta cells.
By analyzing structure activity relationships based on insulin secretion data and pTyr inhibition, we discov-
ered that the disposition of R3 CN group to R2 mitigated the tyrosine kinase inhibitory effect, increased insulin 
secretion and caused calcium influx in RIN-5AH beta cells (compound 15 vs. 8). Furthermore, the TKI effect 
completely disappeared when OCH3 was removed from R6, while the calcium influx effect was still preserved 
(compound 8 vs. 9). The docking simulations also suggested that kinases are not hit by compound 9 and the R2 
positioned CN is crucial for forming H-bonds between protein tyrosine kinase targets (e.g. Abl and Src) and the 
molecule.
Next, patch clamp experiments showed that compound 9 was able to depolarize the cell membrane in RIN-
5AH cells and therefore voltage dependent Ca2+ channels are likely to be involved in its mechanism of action. 
Both GBA and compound 9 depolarized the cell membrane of RIN-5AH beta cells, however compound 9 induced 
a much stronger and longer lasting effect, furthermore a different kinetics of insulin secretion was detected. By 
using ion channel modulators in combination with compound 9, we showed that its insulinotropic effect was 
dependent on K+ and Ca2+ current. By performing comparative combinatorial treatments with GBA, GLP-1 and 
sunitinib, we found that compound 9 had a distinct mechanism of action compared not only to TKIs but to GBA 
and GLP-1 as well. Namely, GLP-1 and sunitinib induced insulin secretion were not sensitive to verapamil or 
nifedipine in contrary to compound 9. This differential analysis further helped us to confirm that GLP-1 receptor 
and TKIs were primarily not involved in its mechanism of action. It is further noticeable that GBA is known to be 
a sulfonylurea drug with very high affinity to both rat and human KATP channels39, in our experiments it showed a 
weaker effect on insulin secretion compared to compound 9. Both RIN-5AH beta cells and pancreatic microislets 
were less sensitive to GBA treatments and a 20–40x higher concentration was necessary to register a significant 
insulin release effect. DAO could also not attenuate the secretagogue effect of GBA in RIN-5AH cells, which 
might be due to the low sensitivity of the cells.
Compound 9 induced the phosphorylation of CAMKII and ERK1/2, which could be a consequence of the 
increased calcium influx. The upregulation of ERK1/2 can be beneficial and might support the survival of beta 
cells similarly to GLP-136. The reduced pERK1/2 level evoked by pre-treatments with KN-62 and EFD, correlated 
with a lower insulin secretion. In spite of ERK1/2 was downregulated by U0126, the compound 9 induced insulin 
secretion was still noticeable, in contrary to another MEK inhibitor, PD184352. These inhibitors affected cell 
viability in a different manner, thus this might serve as an explanation for the dissimilar insulin secretion data. 
It was also described in the literature by others, that PD184352 produced cytotoxic effect in vitro (Schwannoma 
cell lines) and also induced apoptosis in contrast to U012640. In our experiments we also observed a significantly 
decreased viability by treatment with PD184352, but not U0126 (Supplementary Table 1). We hypothesize that 
off-targets of these MEK inhibitors could also play role and more investigation would be needed to clarify this 
phenomenon. Our western blot results suggest that both active ERK1/2 and CAMKII were necessary for com-
pound 9 to exert its insulinotropic effect, furthermore its potency is dependent on Ca2+ and K+ currents. Taken 
into consideration that compound 9 has a quick acting characteristics, it is most likely targeting ion channel(s) 
or acting on their direct regulators. We think that it is not targeting the KATP channel and has a different mode 
of action compared to GBA, since the kinetics and efficiency was not comparable. Finally we tested the effect of 
compound 9 on cell viability and based on our results we found that the insulinotropic action is not in correlation 
with toxicity or stress induced secondary effect.
In summary, we discovered and developed novel quinoline derivatives from the TKI, bosutinib that were able 
to stimulate insulin secretion in RIN-5AH cells. Next, we characterized a highly potent member of this family that 
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exerted its effect through membrane depolarization and calcium influx and confirmed by SAR that it is not acting 
on tyrosine kinases. In order to elucidate the exact molecular mechanism of membrane depolarization and how 
calcium influx is induced by compound 9, further investigations are needed.
Materials and Methods
Compound library. The initial compound library consisting of 558 compounds used in the primary screen 
was selected from the NCL library (Nested Chemical Library) of Vichem Chemie Ltd. The compounds and the 
synthetic routes are described in our patent EP100064, with the application number: 16170166.9–1466. Sunitinib, 
imatinib, bosutinib, tivantinib, sorafenib and dasatinib were also provided by Vichem Chemie Ltd.
Cell culture. RIN-5AH insulinoma beta cell line was cultivated in RPMI 1640 supplemented with 10% FBS, 
2 mM glutamine (Life Technologies) and grown at 37 °C, 5% CO2 in a high humidity atmosphere. 3D InSight™ 
Rat Islet Microtissues were purchased from InSphero and were propagated according to user’s manual.
Insulin ELISA. RIN-5AH beta cells were seeded in 96 well plates (4 × 105) and grown overnight (ON). Cells 
were washed 1x with PBS and treated in medium or HBSS buffer with or without Mg2+ and Ca2+ (HBSS+ + 
and HBSS− ). Standard conditions were 5 μ M and 2 h if not otherwise indicated. For the combinatorial treat-
ments, compounds were mixed and cells were treated for 2 h. The pre-plated 3D InSight™ Rat Islet Microtissues 
(Insphero, Switzerland) were washed 2x in KRBH containing low glucose (131 mM NaCl, 4.8 mM KCl, 1.3 mM 
CaCl2, 25 mM HEPES, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.8 mM glucose) and pre-incubated for 2.5 h at 37 C, 5% 
CO2 in KRBH with low glucose. Treatments were performed in KRBH containing high glucose (16,8 mM). After 
treatments, sample supernatants were assayed immediately or stored at − 20 °C until measurement. Dilutions 
were made if necessary then ELISA was performed according to the user’s manual (Mercodia, Sweden). Plates 
were read on BioTek Elx800 Absorbance reader. Secreted insulin level was normalized to total protein amount in 
RIN-5AH cells. Protein concentration was determined by BCA assay kit (Thermo Scientific) according to user’s 
manual. In microislets the secreted insulin amount was normalized to total insulin. Microislets were lysed using 
KRBH containing 1,25% TX-100.
Docking simulations. The docking calculations were carried out using Schrödinger® Suite 2009 update 
2 molecular modeling program packages (Glide, LigPrep, Maestro, Protein Prep. Wizard). We used the previ-
ously described crystal structure of Abl (3UE4) and Src (4MXO) from the RCSB Protein Data Bank. Protein 
Preparation Wizard was applied to add hydrogens to the protein residues, to remove the water molecules from the 
crystal structure, to assign bond orders and to treat the missing disulfide bonds. The 3D structures of the ligands 
were prepared using LigPrep module with OPLS_2005 force field (epic, pH = 7.4). The described ligands in the 
PDB entry were chosen for receptor model generation. For the docking we used Glide in standard precision (SP) 
mode. The best conformations were saved for each ligand and false conformations were rejected by the energy 
filters.
Determination of total pTyr levels by Flow Cytometry. 1 × 106 RIN-5AH beta cells were seeded in 
6 well plate and incubated overnight. After washing once with PBS, they were treated with compounds at 5 μ M 
and incubated for 2 h at 37C 5% CO2. Cells were washed with ice cold PBS then trypsinized on ice. After 3 min 
incubation samples were collected, centrifuged and resuspended in 750ul PBS. Cells were fixed by adding 1 ml 
4% formaldehyde solution and incubated for 10 min at 37C. Samples were placed on ice, then centrifuged and 
1 ml 90% methanol was added to permeabilize the cells followed by an incubation for overnight (ON) at − 20C. 
Samples were washed 2x with PBS containing 0.5% BSA. 100–100 ul of p-Tyr and IgG Isotype control antibodies 
were added and incubated at room temperature (RT) for 1 h. The p-Tyr antibody and IgG Isotype control anti-
bodies (Cell Signaling, 9411, 5415) were diluted and used at equal concentrations (1 ug/ml). After incubation 
and washing with PBS containing 0.5% BSA, 100 ul PE-conjugated donkey anti-mouse antibody (1:200 dilution, 
Jackson Immuno Research, 715–116–150) was added per sample and incubated for 30 min at RT. Samples were 
washed with PBS containing 0.5% BSA then resuspended in PBS. Measurement was performed on BD Accuri™ 
C6 Cytometer. Analysis and figures were prepared using FlowJo (FlowJo, LLC, Oregon).
Calcium influx measurements on FACS. RIN-5AH beta cells were seeded (2 × 106 cells) on 10 cm plates 
and incubated ON. Cells were loaded with 3 μ M Fluo-4 AM (Molecular Probes, F14201) with addition of a final 
amount of 0.02% Pluronic-F127 (Molecular Probes, P6867) for 45 min at 37C, in 5% CO2. After washing with 
HBSS (Life Technologies) without calcium and magnesium (HBSS− ) cells were trypsinized then washed again 
with HBSS− . Cells were resuspended in 1 ml HBSS containing calcium and magnesium (HBSS+ + ) or HBSS− 
before starting the measurements. Base fluorescent signal was recorded for 30 s in FL-1 channel. Gaps on FL-1/
time graphs indicate the addition of compounds. Then samples were measured continuously for the desired time. 
Unstained cells were used as negative controls. To validate our assay we used the SERCA inhibitor Thapsigargin 
in HBSS− and the Ca2+ ionophore A23187 and GBA in HBSS+ + buffers. Non-stained cells treated with com-
pounds were used as negative control (Supplementary Fig. 7a.). Calcium influx measurements could not be car-
ried out with sunitinib because of its autofluorescent nature. Compounds used in the calcium influx experiments 
were purchased from various sources (Chloroquine diphosphate - Sigma, C6628; Quinidine - Sigma, Q3625; 
Verapamil - Santa Cruz, sc-3590A; Efonidipine HCl monoethanolate - Sigma, E0159; Glibenclamide - Santa Cruz, 
sc-200982; Gatifloxacine - Santa Cruz, sc-204762; Levofloxacine HCl - Santa Cruz, sc-202693; Thapsigargin - 
Serva, 36000; A23187 Calcium ionophore - Sigma, C7522). Quantitative evaluation was done by gating every 5 s 
of mean fluorescence levels in the FL-1/time graphs (Supplementary Fig. 7b.). AUC was calculated from 50s-325s, 
baseline was set for the first untreated 35 s. Data were acquired on BD-FACSCalibur flow cytometer, data visual-
izations and MFI was evaluated with FlowJo software. AUC calculations were prepared in GraphPad Prism 7.00.
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Spinning disc confocal microscopy. RIN-5AH beta cells were plated (30.00 cells) in 35 mm u-Dishes 
(IBIDI, 80136) and incubated overnight at 37 °C, in 5% CO2. Cells were loaded with Fluo-4 AM for 45 min at 
37C, 5% CO2 then washed 2x with HBSS− . Afterwards HBSS+ + was added and base fluorescence signal was 
recorded for 30 s. Treatments were performed by using a perfusion pump (Ismatec) and final concentrations of 
5 μ M for compound 9 and 250 μ M for glibenclamide. Monitoring and recording of fluorescence intensity was 
carried out on an UltraVIEW Vox spinning disk microscope system (PerkinElmer), which was attached to a 
HAMAMATSU ImagEM camera (cooled down to − 80 °C). Calculation of results was done in Volocity software 
(PerkinElmer).
Autofluorescence. Fluorescent signal of 5 μ M compound 9 was recorded in aqueous solution using 0,1% 
DMSO and compared to fluorescein in order to rule out autofluorescent activity (data not shown).
Patch clamp. RIN-5AH cells were trypsinized, centrifuged and resuspended in medium (RPMI-1640 con-
taining 10% FBS and 2 mM glutamine). Cells were transferred into a recording chamber and allowed to settle 
down before beginning a slow perfusion with the external buffer (138.0 mM; NaCl; 5.6 mM KCl; 11.1 mM glucose; 
1.2 mM; MgCl2; 2.6 mM CaCl2; 10.0 mM HEPES). Cells were sealed and patched by applying a gentle negative 
pressure. The components of intracellular solution were: 185 mM potassium-gluconate (Sigma); 13 mM HEPES; 
13 mM NaCl; 1 mM MgCl2; 1 mM ATP (Sigma); 1 mM GTP (Sigma). Holding membrane potential was set to 
− 70 mV for voltage clamp experiments. After patching the cells, for at least 10 s the baseline signal was recorded. 
Local application of drugs onto the cells from a thin glass capillary (similar to the patch-clamp pipette) was done 
using a Picospritzer II instrument (Parker) with a pressure of 5 psi and a pressure pulse lasting for 30 s. Different 
cells were used in voltage clamp and current clamp experiments. Each experiment was repeated 3–4 times and the 
total recording time was set to 2–4 minutes. Graphs were prepared in GraphPad Prism 7.00.
Western Blot. 1.2 × 106 RIN-5AH beta cells were seeded in 6 well plates and incubated overnight in 37 °C 
and 5% CO2. Cells were washed 1x with PBS and treated for the indicated times. In combinatorial treatments, 
cells were pre-treated with inhibitors for 30 min, followed by a 10 min treatment with compound 9. Cells were 
then washed with ice cold PBS and lysed in CelLytic M (Sigma, C2978) lysis buffer supplemented with apro-
tinin (4 μ g/ml), NaF (10 mM), PMSF (1 mM), NaOV (1 mM), Phosphatase inhibitor cocktail 2 (Sigma, P5726). 
Lysate was collected by using cell scrapers. Protein concentration was determined by BCA assay kit according 
to user’s manual. 10–20 μ g of protein was loaded in 9–15% SDS-gels. Gel electrophoresis was performed at 
180 V. Proteins were transferred into nitrocellulose membrane (GE) by wet blotting for 1 h 15 min and 400 mA. 
Membranes were blocked in TBST containing 5% BSA (Sigma) for 1 h at RT following an overnight incubation 
at 4 °C with primary antibodies. Next day HRP-conjugated secondary antibody was applied for 1 h at RT. After 
incubation with antibodies, membranes were washed 3 × 15 min with TBST. Luminescent signal was developed 
with Enhanced ChemiLuminescent (ECL) Kit (PerkinElmer/NEN, NEL104001EA), signal was developed by 
using Hyperfilm TM MP (GE). Membranes were stripped in strip buffer (62.5 mM Tris/HCl pH 6.8; 2% SDS; 
100 mM beta-mercaptoethanol) at 50 °C for 1,5 h and protein loading controls were checked by using total protein 
antibodies or alpha tubulin. The following antibodies were used: p-MEK1/2; p-ERK1/2; p-Tyr and p-Thr (Cell 
Signaling); pSer (Alexis); p-CAMKII (Abcam); ERK1/2 (Life technologies); a-tubulin (Sigma); Goat Anti-Mouse 
IgG secondary Ab (Jackson Immuno Research); Goat Anti-Rabbit IgG Ab (Biorad).
Intracellular ATP level detection. 20.000 cells were plated on flat bottom non-transparent black 96 well 
plates (Costar). Treatment was performed after overnight incubation for the desired time. Medium was removed 
and 80 ul CellTiter-Glo component (Promega) was added in a 1:1 volume to the wells, then plates were incubated 
at RT in dark for 15 min. Luminescence intensity was measured on TECAN Evolution microplate reader.
Measurement of BrdU incorporation. RIN-5AH cells per well were seeded on 96 well plates and incu-
bated overnight at 37 °C and 5% CO2. Treatment was performed in 100 ul per well for 48 h and 72 h. BrdU assay 
was analyzed by using the kit from Cell Signaling Technology (5492) and it was performed according to the user’s 
manual. In brief: 10 ul of 10x BrdU was added 24 h in advance to each sample and incubated at 37 °C and 5% CO2 
until further steps. Luminescence was detected on TECAN Evolution microplate reader.
Apoptosis analysis by Flow Cytometry. Apoptosis was detected by using Annexin V FITC and PI dou-
blestaining (Thermo Scientific, V13242). 300.000 cells were plated on 6 well plates and incubated overnight at 
37 °C and 5% CO2. Cells were treated with the compounds for the desired time. Cells were washed with ice cold 
PBS and trypsinized for 3 min. Then ice cold PBS was added to each sample and centrifuged. Samples were resus-
pended in 100 ul annexin binding buffer and staining was performed according to user’s manual. Samples were 
stored on ice in annexin binding buffer until measurement. A total of 20.000 ungated events were acquired on an 
Accuri C6 Plus Flow Cytometer. Data was analyzed in CFlow data acquisition and analysis software.
Competitive kinase binding assay. Compound 9 and sunitinib were tested against 392 non-mutant and 
59 mutant kinases in a competitive binding assay at 5 μ M using DiscoverX KINOMEscan® technology. Bosutinib 
was screened against 386 non-mutant and 56 mutant kinases. Results are reported in %Ctrl values, the lower 
values refer to stronger hits. We set the cutoff to 35%Ctrl to compare the target profiles of sunitinib, bosutinib and 
compound 9 (for more details see www.discoverx.com).
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